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INTRODUCTION
Endometriosis is a disease in which endometrium
that normally lines the uterus, grows outside the
uterine cavity and is usually related to pelvic pain
and infertility.1 Endometriosis is an estrogen-
dependent disease, therefore it affects not only
women in their reproductive age, but also post-
menopausal women who uses hormone replace-
ment therapy. The prevalence of endometriosis
during reproductive age ranged between 5-10%.2
The role of estrogen in the pathophysiology of
endometriosis has been well known for a long time.
Recent medical treatment is aimed to put the pa-
tient in a hypoestrogen state. Various studies found
that there were sources of estrogen outside the go-
nads (extra-gonad). The adipose tissue and the skin
were found to be able to convert androstenedione
into estrone. Lately, endometriosis lesions itself is
suspected of having the ability to convert andro-
gens to estrogens independently. Accordingly, en-
dometriosis tissue expresses complete steroido-
Abstract
Objective: To assess the estrone (E1), estradiol (E2) and estriol (E3)
blood level and its ratio (E2:E1, E2:E3 and E1:E3) between women
with and without endometriosis.
Method: We performed an analytical cross sectional study with 27
women with endometriosis and 27 women without endometriosis
who met the inclusion criteria. The samples were recruited in Dr.
Cipto Mangunkusumo hospital and other satellite hospitals from Oc-
tober 2012 to April 2013. The blood level of estrogen metabolites
was examined by enzyme-linked immunosorbent assay (ELISA).
Comparison between the two groups was analyzed by using Mann-
Whitney test.
Result: The level of estrone was found to be lower in endometriosis
group compared to that in the control group (54.66 pg/ml vs 73.52
pg/ml, p=0.229). Similarly, the levels of estradiol and estriol were
lower in endometriosis group (29 pg/ml vs 35 pg/ml, p=0.815 and
1.11 pg/ml vs 1.67 pg/ml, p=0.095, consecutively). The E2:E1 ratio
was higher in endometriosis group (0.51 pg/ml vs 0.38 pg/ml,
p=0.164), as well as E2:E3 ratio (26.53 pg/ml vs 21.11 pg/ml,
p=0.223) and the E1:E3 ratio (58.55 pg/ml vs 50.28 pg/ml,
p=0.684). However, all those differences were not statistically sig-
nificant.
Conclusion: The estrone, estradiol and estriol levels in women with
endometriosis were lower compared to those in women without en-
dometriosis. The ratio of E2:E1, E2:E3 and E1:E3 were higher in en-
dometriosis group. However, all those differences failed to reach sta-
tistical significance.
[Indones J Obstet Gynecol 2014; 3: 127-131]
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Abstrak
Tujuan: Menganalisis kadar estron (E1), estradiol (E2) dan estriol
(E3) dalam darah dan rasio E2:E1, E2:E3 dan E1:E3 antara wanita
dengan dan tanpa endometriosis.
Metode: Dikerjakan penelitian dengan desain potong lintang analitik
pada 27 wanita dengan endometriosis dan 27 wanita tanpa en-
dometriosis yang memenuhi kriteria inklusi. Sampel didapatkan dari
Rumah Sakit Dr. Cipto Mangunkusumo dan rumah sakit jejaring lain-
nya periode Oktober 2012-April 2013. Kadar metabolit estrogen
dalam darah diperiksa dengan uji enzyme-linked immunosorbent
(ELISA). Perbandingan data antara dua kelompok dianalisis dengan
uji Mann-Whitney.
Hasil: Kadar estron ditemukan lebih rendah pada kelompok endo-
metriosis dibandingkan kontrol (54,66 pg/ml vs 73,52 pg/ml, p=0,229).
Demikian pula, kadar estradiol dan estriol lebih rendah pada kelompok
endometriosis (29 pg/ml vs 35 pg/ml, p=0,815 dan 1,11 pg/ml vs 1,67
pg/ml, p=0,095, berturut-turut). Rasio E2:E1 lebih tinggi pada kelompok
endometriosis (0,51 pg/ml vs 0,38 pg/ml, p=0,164), demikian pula de-
ngan rasio E2:E3 (26,53 pg/ml vs 21,11 pg/ml , p=0,223) dan rasio E1:E3
(58,55 pg/ml vs 50,28 pg/ml, p=0,684). Namun, semua perbedaan itu ti-
dak signifikan secara statistik.
Kesimpulan: Kadar estron, estradiol dan estriol pada wanita dengan
endometriosis lebih rendah dibandingkan pada wanita tanpa endo-
metriosis. Rasio E2:E1, E2:E3 dan E1:E3 lebih tinggi pada kelompok
endometriosis. Namun, semua perbedaan itu gagal mencapai signifi-
kansi secara statistik.
[Maj Obstet Ginekol Indones 2014; 3: 127-131]
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genic genes, including aromatase. This finding
could change the endometriosis treatment ap-
proaches in the future, because recent treatment
has only aimed the hypothalamus-pituitary-ovari-
an axis to cause a hypoestrogen state in patients.
Along with the discovery of estrogen sources out-
side the gonads, current treatment has been deve-
loping with the application of aromatase inhibitor
drugs to suppress estrogen production outside the
gonad.3,4
Similar to endometriosis, breast cancer is also
known to be estrogen-dependent. Estrogen has an
important role in promoting cancer cells growth.
Likewise in endometriosis, breast cancer itself also
produces estrogens through aromatase and steroid
sulfatase pathways. The enzyme 17 -hydroxyste-
roid dehydrogenase (17 -HSD) must also play a
role in the regulation of estradiol and estrone. A
study found that a low ratio between 17 -HSD type
2 and 1 gave a higher incidence of recurrence in
post-menopausal breast cancer patients treated
with tamoxifen. Patients with high level of 17 -HSD
type 1 have a higher risk for relapse. The expression
of the enzyme 17 -HSD type 1 and 2 in breast can-
cer were different to that in normal mammary
glands, giving a clear prognosis in breast cancer
cases.5,6
Mechanisms of estradiol metabolism in the body
is by converting estradiol (E2) into estrone (E1).
Furthermore, the estrone is converted into metabo-
lites ring A and ring D (estriol/E3). Biologically, es-
tradiol is the most active form of estrogen. Com-
parison of these three hormone levels is E2:E1:E3
= 10:5:1.7 Similar to breast cancer, the enzyme 17 -
HSD plays an important role in estrogen metabo-
lism in endometriosis. In a recent study, it was
found that the ratio between 17 -HSD type 1 and
type 2 in endometriosis lesions is higher compared
to normal endometrial tissue. This study was con-
ducted in patients with endometriosis and normal
subjects. In other words, it indicates a high synthe-
sis of estradiol in the lesion.8 However, no study has
observed the ratio of estradiol, estrone, and estriol
in patients with endometriosis and normal women
without endometriosis. The role of estrogen meta-
bolites derived from the metabolism of estrogen is
not yet widely known. While the metabolites was
initially considered to have no biological activity, re-
cent research showed estrogenic effects from the
hormone metabolites.5 The finding raises the
thought whether the metabolism of estrogen meta-
bolites also have a role in the pathophysiology of
endometriosis.
This study is particularly aimed to assess es-
trone (E1), estradiol (E2) and estriol (E3) level and
its ratio (E2:E1, E2:E3 and E1:E3) between women
with and without endometriosis. Thus, it is hoped
to give a better understanding on the role of estro-
gen metabolites on the pathogenesis of endome-
triosis to help develop new strategies of endome-
triosis treatment approach in the future and to
guide further research on drugs influencing estro-
gen metabolites.
METHODS
This study is an analytical cross sectional study on
27 women with endometriosis and 27 normal
women without endometriosis who met the inclu-
sion criteria. The subjects were recruited in Dr.
Cipto Mangunkusumo hospital and other satellite
hospitals from October 2012 to April 2013.
The inclusion criteria in endometriosis group
were women diagnosed with endometriosis
through laparoscopy or laparotomy procedure,
having regular menstrual cycle, aged 20-45 years
old, body mass index (BMI) 19-29 kg/m2, and will-
ing to participate in the study. The inclusion crite-
ria in control group were diagnosed as free of en-
dometriosis through laparoscopy or laparotomy or
underwent caesarean section and being declared
as free of endometriosis; having regular menstrual
cycle and willing to participate in the study. The
exclusion criteria applied to both groups were use
of hormonal therapy in the last three months, pres-
ence of other estrogen-dependent gynecologic con-
ditions such as uterine myoma, uterine hyperplasia
or endometrial carcinoma, presence of breast car-
cinoma, or refused to participate in the study.
For all the included paricipants, the data regard-
ing menstrual cycle, any obstetric diagnosis, sur-
gery date and pathology examination result were
collected. For measuring the blood hormone level,
a five cc blood was drawn via venipuncture (day
7-15 in menstrual cycle or following surgery sched-
ule for endometriosis group). Furthemore, the level
of estradiol, estriol and estrone were examined by
using enzyme-linked immunosorbent assay (ELISA)
in Makmal Terpadu Laboratory Faculty of Medicine
University of Indonesia.
The statistical analysis was conducted by using
SPSS program 20th version. Since the data distribu-
tion was not normal, the data was presented in me-
dian value instead of mean value and the compari-
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son of estradiol, estrone and estriol levels and its
ratio between two groups was analyzed by using
Mann-Whitney test.
RESULTS
Characteristics of Research Subjects
Fifty-four patients were recruited in the study, in
which 27 patients diagnosed with endometriosis
were included in the study group. The other 27
women who did not have endometriosis were in-
cluded as control group. There were statistically
significant differences regarding age and parity
characteristic between endometriosis and control
group. In contrast, there was no difference about
BMI between those two groups.
Comparison of Estrone, Estradiol and Es-
triol Level between Women with and with-
out Endometriosis
Because the data distribution was not normal, fur-
ther analysis was carried out by Mann-Whitney
test. Table 2 showed that the level of estrone (E1)
hormone was found to be lower in endometriosis
group compared to that in the control group (54.66
pg/ml vs 73.52 pg/ml, p=0.229). The similar re-
sults were found for estradiol (E2) and estriol (E3)
hormone levels. Compared to control group, the
level of estradiol and estriol were lower in en-
dometriosis group (29 pg/ml vs 35 pg/ml, p=0.815
and 1.11 pg/ml vs 1.67 pg/ml, p=0.095, consecu-
tively). However, the differences in estrogen level
were not statistically significant since p>0.05.
Table 2. Comparison of Estrone, Estradiol and Estriol
Level between Women with and without Endometriosis.
Hormone
Median (Mean Rank) (pg/ml)
p
Endometriosis Control
Estrone 54.66 (24.93) 73.52 (30.07) 0.229
Estradiol 29.00 (27.00) 35.00 (28.00) 0.815
Estriol 1.11 (23.93) 1.67 (31.07) 0.095
Comparison of Ratio between Estradiol and
Estrone, Estradiol and Estriol, Estrone and
Estriol in Women with and without En-
dometriosis
Table 3 showed that the estradiol-estrone ratio
(E2:E1 ratio) was higher in endometriosis group
(0.51 pg/ml vs 0.38 pg/ml, p=0.164), as well as the
estradiol-estrone ratio (E2:E3 ratio), which is
higher in endometriosis group (26.53 pg/ml vs
21.11 pg/ml, p=0.223). However, both differences
failed to reach statistical significance. In the mean-
while, the difference of the estrone-estriol ratio
(E1:E3) was also not statistically significant be-
tween two groups, although the ratio is found to
be lower in control group (58.55 pg/ml vs 50.28
pg/ml in control group, p=0.684).
Table 3. Comparison of Ratio between Estradiol and Es-
trone, Estradiol and Estriol, Estrone and Estriol in Women
with and without Endometriosis.
Hormone
Ratio
Median (Mean Rank) (pg/ml)
p
Endometriosis Control
E2:E1  0.51 (30.48)  0.38 (24.52) 0.164
E2:E3 26.53 (30.11) 21.11 (24.89) 0.223
E1:E3 58.55 (28.37) 50.28 (26.63) 0.684
Table 1. Characteristics of Research Subjects.
Variable Endometriosis Group (n=27) Control Group (n=27) p
Age
20-40 years 19 (43.2%) 25 (56.8%) 0.036
>40 years 8 (80.0%) 2 (20.0%)
Parity
Parity 0 17 (73.0%) 0 (0,0%) 0.000
Parity   1 10 (27%) 27 (100%)
Body Mass Index (BMI)
BMI 19-24 21 (47.7%) 23 (52.3%) 0.484
BMI 25-29 6 (60.0%) 4 (40.0%)
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DISCUSSION
Endometriosis is a well-known estrogen-depend-
ent disease. However, no study has analyzed the
systemic estrogen metabolism in endometriosis
compared to that in women without endome-
triosis. Recent studies have identified the process
of local estrogen metabolism by endometriosis le-
sion.3,4 Thus, this study aimed to analyze whether
systemic estrogen metabolism is in accordance
with its local metabolism in endometriosis. In this
study, the blood serum estrogen levels were exam-
ined by ELISA test. The ratio between estrogen me-
tabolites, comprising of estradiol to estrone, estra-
diol to estriol, and estrone to estriol, in women
with and without endometriosis were compared.
The diagnosis of endometriosis and non-endo-
metriosis in the study was confirmed by laparos-
copy or laparotomy. Therefore, it improves the re-
liability and validity of this study because it re-
duces the risk of false positives and false negatives
during sample selection.
In patient characteristics, there was no diffe-
rence regarding BMI between two groups, in which
the percentage of normal and overweight-classified
BMI was relatively similar. Nevertheless, significant
differences were seen in age and parity charac-
teristics. In women with endometriosis, the data
showed that approximately 80% of the patients
were older than 40 years of age. All infertile pa-
tients with nulliparity were identified as endome-
triosis group (100%). These significantly different
results may be due to the relatively small sample
size. This is attributable to the limited time and
cost during study completion.
The relatively small sample size also affected the
data distribution, where the data distribution is not
normal based on normality test. Thus, either me-
dian or mean rank instead of data mean, were used
to analyze the difference between the two study
groups.
The estradiol level obtained in women with en-
dometriosis is lower in comparison to women
without endometriosis. This result is not in agree-
ment with the study conducted by Bulun et al who
used Nothern blot analysis. Bulun et al described
a transcription process of 17 -HSD type 1 catalyz-
ing estrone to estradiol-17  in ectopic endome-
trium and endometriosis. Estradiol levels in the tis-
sue was found to be very high due to excessive pro-
duction by aromatase activity, transcription en-
zyme 17 -HSD type 1 and accumulation of estra-
diol which was failed to be metabolized due to de-
ficient 17 -HSD type 2.4 However, the study strictly
measured local estrogen activity in the endome-
triosis lesions, not the systemic estrogen activity.
Similar to this study, estrone and estriol levels in
the endometriosis group were found to be lower
compared to those in women without endome-
triosis.
During growth of endometriosis, there are two
intrinsic molecular abnormalities playing an im-
portant role and is related to estrogen. These in-
clude the high levels of aromatase enzyme, cy-
tokines and tissue metalloproteinases, as well as
deficiency of 17 -HSD type 2 as described earlier.
The high production of aromatase enzyme caused
by high inflammation process, further increasing
the production of PGE2 and aromatase. Increased
activity of aromatase leads to high local estrogen
production. Deficiency of 17 -HSD type 2 also in-
hibits the metabolism of estradiol into estrone,
thus causing estradiol to accumulate in the tissue.4
Consequently, the ratio E2:E1 and E2:E3 was sup-
posed to be increased in women with endome-
triosis. To verify that hypothesis, the ratio of each
of these estrogen hormones was assessed as the
main core of this research. The ratio of E2:E1 re-
vealed that women with endometriosis have a
higher ratio of E2:E1 than women without en-
dometriosis. Similarly, the ratio of E2:E3 was found
to be higher in women with endometriosis. These
results were consistent with the hypothesis of this
study. However, both differences were not statisti-
cally significant.
In addition, similar to the ratio of hormones
E2:E3 and E2:E1, the ratio of E1:E3 was found to
be higher in endometriosis group when compared
to the control group. This result explains that in
endometriosis, there is an increased activity of the
enzyme 17 -HSD type 1 converting estrone to es-
tradiol, so that estradiol level increases in the tis-
sue,8 however, estrone itself is unsuccessfully me-
tabolized into its weaker form, estriol.
No statistical siginificant results in this study
show that not enough evidence is available to sup-
port the hypothesis that systemic estrogen meta-
bolism cannot convey the high local estrogen me-
tabolism in endometriosis lesion. Regardless of the
insignificant result, the ratio of E2:E3; E2:E1 and
E1:E3 is higher in women with endometriosis. This
may imply that the metabolism of estrogen has an
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important role in the development of endome-
triosis. However, estrogen level is not the single ab-
solute factor, because there are many other factors
that play a role in the development of endome-
triosis, such as the environment, enzyme activity,
immune defects, and genetics. In general, this study
decribes that women with high levels of estrogen
metabolism are at higher risk for developing an es-
trogen-dependent disease.
CONCLUSION
The estrone, estradiol and estriol level in women
with endometriosis group was lower compared to
those in women without endometriosis group,
however the differences were not statiscally sig-
nificant. The ratio E2:E1, E2:E3 and E1:E3 was
higher in endometriosis group compared to those
in non-endometriosis group, however, the differ-
ences also failed to reach statistical significance.
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